



Press Release

Thursday, July 28, 2011

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB ANNOUNCES US FDA APPROVAL FOR ACARBOSE TABLETS

Pharma division's approvals gaining momentum

July 28, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Acarbose Tablets, 25mg, 50mg and 100 mg. Acarbose is a niche anti-diabetic drug used to treat type 2 diabetes mellitus.

According to March 2011 IMS data, total US market for Acarbose Tablets approximated to USD 21 Million with no Indian generic players in the market.

The Pharma division has a total of 37 filings with US FDA (21 under the PEPFAR programme and 16 as Generics). Approvals to date are 22 (17 under PEPFAR and 5 Generics).

This product will be marketed and sold by Perrigo under a profit share partnership. Product is expected to be launched shortly, within Q3 '2011.

About Acarbose Tablets

Acarbose Tablets are oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes Mellitus. Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Acarbose Tablets are contraindicated in patients with known hypersensitivity to the drug and in patients with diabetic ketoacidosis or cirrhosis, in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction. It is available in bottles of 100s in 25mg, 50mg & 100mg.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.



The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u> Mr. Manish Gupta – CEO - Pharma +91 80 6784 0112 <u>Investors:</u> Mr. Kannan. N: +91 98450 54745 Mr Ajay Singh: +91 80 6784 0813	<u>PR Consultancy</u> Corporate Voice/Weber Shandwick Mahesh Nair: +91 9880376648 maheshn@corvoshandwick.co.in Hiba Kunil: +91 98807 26372 hiba@corvoshandwick.co.in
---	--

